Details for New Drug Application (NDA): 021866
✉ Email this page to a colleague
NDA 021866 describes ABILIFY, which is a drug marketed by Otsuka and Otsuka Pharm Co Ltd and is included in seven NDAs. It is available from one supplier. There are thirty-seven patents protecting this drug and three Paragraph IV challenges. Additional details are available on the ABILIFY profile page.
The generic ingredient in ABILIFY is aripiprazole. There are forty-nine drug master file entries for this compound. Forty-nine suppliers are listed for this compound. Additional details are available on the aripiprazole profile page.
The generic ingredient in ABILIFY is aripiprazole. There are forty-nine drug master file entries for this compound. Forty-nine suppliers are listed for this compound. Additional details are available on the aripiprazole profile page.
Summary for 021866
| Tradename: | ABILIFY |
| Applicant: | Otsuka |
| Ingredient: | aripiprazole |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 021866
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INTRAMUSCULAR | Strength | 9.75MG/1.3ML (7.5MG/ML) | ||||
| Approval Date: | Sep 20, 2006 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
